Evidence Snapshot

5-hydroxytryptamine receptor 1B

CHEMBL3459 SINGLE PROTEIN Rattus norvegicus

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:10:32Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 1:10 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL3459

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 1B as ChEMBL target CHEMBL3459, mapped to UniProt P28564. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

5-hydroxytryptamine receptor 1B

SINGLE PROTEIN · Rattus norvegicus

As of 2026-09-13

ChEMBL target ID

CHEMBL3459

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P28564

5-hydroxytryptamine receptor 1B

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5-hydroxytryptamine receptor 1B matters

As of 2026-09-13

5-hydroxytryptamine receptor 1B is reviewed as 5-hydroxytryptamine receptor 1B (UniProt P28564); the current evidence base includes 71 approved drugs, 1334 compounds, and 123 assays, with lead potency reaching pChEMBL 10.0.

Protein context

5-hydroxytryptamine receptor 1B

5-hydroxytryptamine receptor 1B Sequence length is 386 aa.

Review this target as 5-hydroxytryptamine receptor 1B, mapped to UniProt P28564. Sequence length is 386 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P28564 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 71 approved drugs, 1334 compounds, and 123 assays for this target. The dominant activity type is IC50. CHEMBL442 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL442 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine

71 approved pChEMBL 10.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 1B matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P28564, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1334

Total Compounds

123

Total Assays

Approved Drugs

IC50: 1093.0, KI: 1073.0, EC50: 2.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL442	10.0	Ki	Approved
No preferred name CHEMBL442	9.7	IC50	Approved
No preferred name CHEMBL1732	9.4	Ki	Approved
No preferred name CHEMBL147503	9.3	IC50	—
No preferred name CHEMBL26379	9.1	IC50	—

Approved Drugs

Structure	Compound	First Approval
	RALOXIFENE CHEMBL81	1997
	OLANZAPINE CHEMBL715	1996
	CARVEDILOL CHEMBL723	1995
	SUMATRIPTAN CHEMBL128	1992
	CLOZAPINE CHEMBL42	1989
	PERGOLIDE CHEMBL531	1988
	ASTEMIZOLE CHEMBL296419	1988
	OXYMETAZOLINE CHEMBL762	1986
	BUSPIRONE CHEMBL49	1986
	PINDOLOL CHEMBL500	1982
	TRAZODONE CHEMBL621	1981
	BROMOCRIPTINE CHEMBL493	1978
	CLEMASTINE CHEMBL1626	1977
	PROPRANOLOL CHEMBL27	1967
	METHYSERGIDE CHEMBL1065	1962
	FLUPHENAZINE CHEMBL726	1959
	ERGOTAMINE CHEMBL442	1948
	METHYLERGONOVINE CHEMBL1201356	1946
	DIHYDROERGOTAMINE CHEMBL1732	1946

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:10:32Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 1:10 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL3459